We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Rituximab for Severe Mucous Membrane Pemphigoid Safe Enough to Be Drug of First Choice?

Michael Hertl, MD; Philippe Bernard, MD; Luca Borradori, MD
Arch Dermatol. 2011;147(7):855-856. doi:10.1001/archdermatol.2011.167.
Text Size: A A A
Published online


In this issue of the Archives, Le Roux-Villet et al1 describe 25 patients with mucous membrane pemphigoid (MMP) who had either extensive disease for a mean of 32 months, ie, progressive eye and/or oral/tracheal involvement or were refractory to the initially applied immunosuppressive or immunomodulatory drugs. The cohort of patients with MMP had either ocular (n  =  10) and/or extraocular involvement (n  =  15) and received 1 or 2 cycles of rituximab (each cycle consisting of rituximab, 4   ×  375 mg/m2 administered intravenously at weekly intervals). After the first rituximab cycle, a total of 68% (17 of 25) of patients with MMP experienced complete clinical remission within 12 weeks, while an additional 5 of 25 patients required a second cycle of rituximab to achieve clinical remission. Overall, only 3 of 25 patients (12%) did not experience clinical remission with rituximab treatment. Most of the patients did not continue adjuvant immunosuppressive drugs and received only concomitant immunomodulatory treatment with dapsone or sulfasalazine during rituximab treatment. Of the 22 patients in complete remission, 10 developed a clinical relapse within 4 months, suggesting a short-lived effect of rituximab. Of note, 3 of 25 patients (12%) developed severe infections within 4 months after rituximab treatment and 2 patients died.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

5 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles